AZTA · Insider Trading
Azenta, Inc.
Every open-market purchase and sale reported by AZTA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-23 | Martin D Madaus | Interim CEO | F | −1,456 | −$49.91K |
| 2026-09-16 | Ephraim Starr | SVP, Gen Counsel & Secretary | A | +15,272 | — |
| 2026-09-16 | Olga Pirogova | SVP and CHRO | A | +15,272 | — |
| 2026-09-16 | Lawrence Y. Lin | EVP, CFO and Treasurer | A | +30,544 | — |
| 2026-09-16 | Erik J. Bello | VP Chief Accounting Officer | A | +4,586 | — |
| 2026-09-16 | William E. Martin III | President Multiomics | A | +15,272 | — |
| 2026-09-16 | Martin D Madaus | Interim CEO | A | +36,653 | — |
| 2026-08-11 | Olga Pirogova | SVP and CHRO | F | −1,085 | −$34.76K |
| 2026-08-04 | Ephraim Starr | SVP, Gen Counsel & Secretary | Buy | +335 | +$8.10K |
| 2026-05-19 | William L Cornog | Director | Buy | +10,000 | +$163.80K |
| 2026-05-18 | Ephraim Starr | SVP, Gen Counsel & Secretary | F | −3,621 | −$58.01K |
| 2026-05-12 | Quentin Koffey | Director | A | +5,663 | — |
| 2026-02-06 | William L Cornog | Director | — | — | — |
| 2026-02-06 | Tina Susan Nova | Director | A | +5,663 | +$157.71K |
| 2026-02-06 | Erica McLaughlin | Director | A | +5,663 | +$157.71K |
| 2026-02-06 | Dipal Doshi | Director | A | +5,663 | +$157.71K |
| 2026-02-06 | Martin D Madaus | Director | A | +5,663 deriv. | — |
| 2026-02-06 | Frank Casal | Director | A | +7,243 | +$201.72K |
| 2026-02-06 | Robyn C Davis | Director | A | +5,663 deriv. | — |
| 2026-02-06 | William L Cornog | Director | A | +5,663 deriv. | — |
| 2025-12-03 | John Marotta | President and CEO | A | +118,194 | — |
| 2025-11-25 | Martin D Madaus | Director | — | — | — |
| 2025-11-25 | Lawrence Y. Lin | EVP, CFO and Treasurer | A | +36,681 | — |
| 2025-11-25 | Ginger Zhou | SVP and GM, Multiomics | A | +13,042 | — |
| 2025-11-25 | William L Cornog | Director | — | — | — |
| 2025-11-25 | William L Cornog | Director | Buy | +7,000 | +$189.88K |
| 2025-11-25 | Ephraim Starr | SVP, Gen Counsel & Secretary | A | +34,235 | — |
| 2025-11-25 | John Marotta | President and CEO | A | +122,269 | — |
| 2025-11-25 | Olga Pirogova | SVP and CHRO | A | +16,303 | — |
| 2025-11-17 | Olga Pirogova | SVP and CHRO | F | −1,553 | −$46.20K |
| 2025-11-17 | John Marotta | President and CEO | F | −10,980 | −$326.65K |
| 2025-11-17 | Ginger Zhou | SVP and GM, Multiomics | F | −1,118 | −$33.26K |
| 2025-11-17 | Lawrence Y. Lin | EVP, CFO and Treasurer | F | −3,039 | −$90.41K |
| 2025-11-14 | Ginger Zhou | SVP and GM, Multiomics | Sell | −1,085 | −$30.97K |
| 2025-11-14 | John Marotta | President and CEO | Buy | +1,000 | +$25.99K |
| 2025-11-14 | Alan J Malus | Director | Buy | +12,000 | +$319.80K |
| 2025-11-14 | Olga Pirogova | SVP and CHRO | Sell | −1,085 | −$30.97K |
| 2025-09-12 | John Marotta | President and CEO | Sell | −316 | −$9.29K |
| 2025-08-13 | Olga Pirogova | SVP and CHRO | D | −1,085 | −$30.97K |
| 2025-08-13 | Ginger Zhou | SVP and GM, Multiomics | D | −1,085 | −$30.97K |
| 2025-08-12 | Lawrence Y. Lin | EVP, CFO and Treasurer | Buy | +2,500 | +$69.90K |
| 2025-06-04 | John Marotta | President and CEO | A | +5,433 | +$149.38K |
| 2025-06-04 | John Marotta | President and CEO | A | +1,000 | +$25.99K |
| 2025-06-03 | Alan J Malus | Director | A | +12,000 | +$319.80K |
| 2025-05-27 | Ephraim Starr | SVP, Gen Counsel & Secretary | A | +37,779 | +$1.01M |
| 2025-05-20 | William L Cornog | Director | A | +7,000 | +$189.88K |
| 2025-05-12 | John Marotta | President and CEO | A | +5,433 | +$150.00K |
| 2025-05-12 | Lawrence Y. Lin | EVP, CFO and Treasurer | A | +6,000 | +$165.30K |
| 2025-02-13 | Lawrence Y. Lin | EVP, CFO and Treasurer | A | +2,200 | +$101.20K |
| 2025-02-11 | Robyn C Davis | Director | A | +4,040 | +$211.37K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Quentin Koffey | Director | 4,622,450 | $169.09M |
| John Marotta | President and CEO | 213,193 | $7.80M |
| Jason Joseph | SVP, General Counsel, Secy. | 112,564 | $4.12M |
| Lawrence Y. Lin | EVP, CFO and Treasurer | 110,199 | $4.03M |
| Ephraim Starr | SVP, Gen Counsel & Secretary | 84,000 | $3.07M |
| Olga Pirogova | SVP and CHRO | 47,225 | $1.73M |
| William L Cornog | Director | 42,750 | $1.56M |
| Martin D Madaus | Interim CEO | 42,602 | $1.56M |
| Ginger Zhou | SVP and GM, Multiomics | 38,755 | $1.42M |
| Robyn C Davis | Director | 33,627 | $1.23M |
| William E. Martin III | President Multiomics | 33,062 | $1.21M |
| David Dong Wang | SVP & GM, SMS | 23,974 | $876.97K |
| Herman Cueto | EVP, Chief Financial Officer | 23,892 | $873.97K |
| Erica McLaughlin | Director | 22,521 | $823.82K |
| Frank Casal | Director | 21,803 | $797.55K |
| Alan J Malus | Director | 17,035 | $623.14K |
| Tina Susan Nova | Director | 15,772 | $576.94K |
| Dipal Doshi | Director | 9,703 | $354.94K |
| Violetta Hughes | VP, Chief Accounting Officer | 9,603 | $351.28K |
| Erik J. Bello | VP Chief Accounting Officer | 4,586 | $167.76K |
| Didier Hirsch | Director | 3,465 | $126.75K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AZTA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.